PMID- 14605017
OWN - NLM
STAT- MEDLINE
DCOM- 20031120
LR  - 20181130
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 108
IP  - 16 Suppl 1
DP  - 2003 Oct 21
TI  - Application of current guidelines to the management of unstable angina and 
      non-ST-elevation myocardial infarction.
PG  - III28-37
AB  - Unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI) is a common 
      but heterogeneous disorder with patients exhibiting widely varying risks. Early 
      risk stratification is at the center of the management program and can be 
      achieved using clinical criteria and biomarkers, or a combination. In addition to 
      anti-ischemic therapy and aspirin, the thienopyridine clopidogrel is indicated 
      except in patients who are potential candidates for urgent coronary artery bypass 
      grafting (CABG). Platelet glycoprotein (GP) IIb/IIIa antagonists are indicated in 
      high-risk patients likely to undergo percutaneous coronary intervention (PCI) but 
      are not indicated in the management of lower-risk patients who do not undergo 
      PCI. There is a growing body of evidence to support the substitution of the 
      low-molecular-weight heparin (LMWH) enoxaparin for unfractionated heparin (UFH). 
      Three recent trials have demonstrated the benefit of an early invasive strategy 
      with catheterization followed by revascularization in patients at high and 
      intermediate risk. Lower-risk patients should undergo early noninvasive stress 
      testing. An intensive program of secondary prevention is mandatory and should be 
      begun before hospital discharge.
FAU - Braunwald, Eugene
AU  - Braunwald E
AD  - TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and The 
      Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. 
      ebraunwald@partners.org
LA  - eng
PT  - Guideline
PT  - Journal Article
PT  - Practice Guideline
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Anticoagulants)
RN  - 0 (Biomarkers)
RN  - 0 (Peptides)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - NA8320J834 (Eptifibatide)
SB  - IM
MH  - Angina, Unstable/diagnosis/*therapy
MH  - Anticoagulants/therapeutic use
MH  - Biomarkers/analysis
MH  - Disease Management
MH  - Electrocardiography
MH  - Eptifibatide
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/diagnosis/*therapy
MH  - Myocardial Revascularization/methods
MH  - Peptides/therapeutic use
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/analysis/antagonists & inhibitors
MH  - Risk Assessment
MH  - Sex Factors
EDAT- 2003/11/08 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/11/08 05:00
PHST- 2003/11/08 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/11/08 05:00 [entrez]
AID - 108/16_suppl_1/III-28 [pii]
AID - 10.1161/01.CIR.0000086952.14979.32 [doi]
PST - ppublish
SO  - Circulation. 2003 Oct 21;108(16 Suppl 1):III28-37. doi: 
      10.1161/01.CIR.0000086952.14979.32.